VJDementia is committed to improving our service to you

Share this video  

VJDementia is committed to improving our service to you

AD/PD 2022 | Antibody-based therapy in Alzheimer’s disease: future outlook

Greg Lemke, PhD, Salk Institute for Biological Studies, San Diego, CA, discusses the importance and where we are concerning the progress in the field of Alzheimer’s disease therapies. Still in the early stages, there is much we do not know regarding antibody-based treatment against amyloid β, and further studies are needed to shed light on their mechanisms. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.